OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
41 hedge funds and large institutions have $16.9M invested in OncoMed Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 7 closing their positions.
30% more capital invested
Capital invested by funds: $13.1M → $16.9M (+$3.88M)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
2% less funds holding
Funds holding: 42 → 41 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$481K |
| 2 |
BC
Birchview Capital
Burlington,
Vermont
|
+$163K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$63.4K |
| 4 |
AP
Appleton Partners
Boston,
Massachusetts
|
+$53.9K |
| 5 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$53.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
-$1.42M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$120K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$64K |
| 4 |
D.E. Shaw & Co
New York
|
-$58.5K |
| 5 |
Primecap Management
Pasadena,
California
|
-$44.7K |
OMED Hedge Fund Activity: Q1 2019 in Review
41 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q1 2019, worth a combined $16.9M — up 30% from $13.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of OMED and 6 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $481K. The largest seller was Harbourvest Partners, exiting entirely with an estimated $1.42M sold.
- 41 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q1 2019, down from 42 in Q4 2018.
- Funds reported $16.9M of OncoMed Pharmaceuticals, Inc. stock for Q1 2019, up 30% quarter-over-quarter.
- 6 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q1 2019 and 7 closed out, a net change of -1 holder.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q1 2019 was Renaissance Technologies, an estimated $481K added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q1 2019 was Harbourvest Partners, an estimated $1.42M sold.
Based on aggregated 13F filings for Q1 2019.